Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease

Journal of Clinical Pharmacology

Volumn 52, Issue 10, 2012, Pages 1468-1481

  Knebel, William ^a   Rao, Niranjan ^b   Uchimura, T ^b   Mori, Akihisa ^b   Fisher, Jeannine ^a   Gastonguay, Marc R ^a   Chaikin, Philip ^c,d  

^a Metrum Research Group LLC   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c Chaikin Associates LLC   (United States)

^d Kyowa Pharmaceuticals Inc   (United States)

Author keywords

Istradefylline; Parkinson disease; population pharmacokinetic and pharmacodynamic modeling

Indexed keywords

CARBIDOPA; ISTRADEFYLLINE; LEVODOPA; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROBABILITY; STEADY STATE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIAS; HUMANS; MODELS, BIOLOGICAL; NAUSEA; PARKINSON DISEASE; PURINES;

EID: 84870415707     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011420566     Document Type: Article

References (20)

1. Cieslak M, Komoszynski M, Wojtczak A.. Adenosine A(2A) receptors in Parkinson's disease treatment. Purinergic Signal. 2008 ; 4: 305-312
2. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008 ; 63: 295-302
3. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008 ; 70: 2233-2240
4. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008 ; 23: 2177-2185
5. Hauser RA, Hubble JP, Truong DD.. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003 ; 61: 297-303
6. Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. J Clin Pharmacol. :
7. Rao N, Chaikin P, Dvorchik B, Mori A, Uchimura T.. Evaluation of the pharmacokinetic interaction of istradefylline and ketoconazole. Parkinsonism Rel Disord. 2007 ; 13: S104
8. Rao N, Chaikin P, Dvorchik B, Sussman N, Mori A, Uchimura T.. Effect of moderate hepatic impairment and cigarette smoking on the pharmacokinetics of istradefylline. Parkinsonism Rel Disord. 2007 ; 13: S104
9. Metrum Institute. NMQual: NONMEM installation utility. http://metruminstitute.org. Published 2008.
10. Agresti A Categorical Data Analysis. New York, NY: John Wiley & Sons Inc ; 1990 :
11. Harrell FE Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag ; 2001 :
12. Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM.. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009 ; 68: 669-681
13. Burnham KP, Anderson DR Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. New York, NY: Springer-Verlag ; 2002 :
14. Parke J, Holford NH, Charles BG.. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999 ; 59: 19-29
15. Ette EI, Onyiah LC.. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization. Eur J Drug Metab Pharmacokinet. 2002 ; 27: 213-224
16. Efron B.. Missing data, imputation, and the bootstrap. J Am Stat Assoc. 1994 ; 89: 463-479
17. Ette EI.. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997 ; 37: 486-495
18. Yano Y, Beal SL, Sheiner LB.. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Biopharm. 2001 ; 28: 171-192
19. Rao N, Chaikin P, Dvorchik B, Mori A, Uchimura T.. Effect of moderate hepatic impairment and cigarette smoking on the pharmacokinetics of istradefylline. Parkinsonism Rel Disord. 2007 ; 13: S104
20. Brooks DJ, Doder M, Osman S, et al. Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse. 2008 ; 62: 671-681